Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005

Overview

Journal Urology

Specialty Urology

Date 2007 Jun 19

PMID 17572194

Citations 133

Authors

Danil V Makarov

Bruce J Trock

Elizabeth B Humphreys

Leslie A Mangold

Patrick C Walsh

Jonathan I Epstein

Alan W Partin

Affiliations

Soon will be listed here.

Abstract

Objectives: To update the 2001 "Partin tables" with a contemporary patient cohort and revised variable categorization, correcting for the effects of stage migration.

Methods: We analyzed 5730 men treated with prostatectomy (without neoadjuvant therapy) between 2000 and 2005 at the Johns Hopkins Hospital. Average age was 57 years. Multivariable logistic regression was used to estimate the probability of organ-confined disease, extraprostatic extension, seminal vesicle involvement, or lymph node involvement. Predictor variables included preoperative prostate-specific antigen (PSA) level (0 to 2.5, 2.6 to 4.0, 4.1 to 6.0, 6.1 to 10.0, and greater than 10.0 ng/mL), clinical stage (T1c, T2a, and T2b/T2c), and biopsy Gleason score (5 to 6, 3 + 4 = 7, 4 + 3 = 7, or 8 to 10). Bootstrap resampling was used to generate 95% confidence intervals for predicted probabilities.

Results: Seventy-seven percent of patients had T1c, 76% had Gleason score 5 to 6, 80% had a PSA level between 2.5 and 10.0 ng/mL, and 73% had organ-confined disease. Nomograms were developed for the predicted probability of pathologically organ-confined disease, extraprostatic extension, seminal vesicle invasion, or lymph node involvement. The risk of non-organ-confined disease increased with increases in any individual prognostic factor. The dramatic decrease in clinical stage T2c compared with the patient series used in the previous models resulted in T2b and T2c being combined as a single predictor in the nomogram.

Conclusions: These updated "Partin tables" were generated to reflect trends in presentation and pathologic stage for men diagnosed with clinically localized prostate cancer at our institution. Clinicians and patients can use these nomograms to help make important decisions regarding management of prostate cancer.

Citing Articles

Current status and therapeutic value of extended pelvic lymph node dissection during radical prostatectomy for prostate cancer.

Morizane S, Takenaka A Prostate Int. 2025; 12(3):117-127.

PMID: 39816936 PMC: 11733762. DOI: 10.1016/j.prnil.2024.03.002.

Appropriateness of Imaging for Low-Risk Prostate Cancer-Real World Data from the Pennsylvania Urologic Regional Collaboration (PURC).

Mercedes R, Head D, Zook E, Eidelman E, Tomaszewski J, Ginzburg S Curr Oncol. 2024; 31(8):4746-4752.

PMID: 39195337 PMC: 11352630. DOI: 10.3390/curroncol31080354.

A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.

Rade M, Kreuz M, Borkowetz A, Sommer U, Blumert C, Fussel S Mol Med. 2024; 30(1):19.

PMID: 38302875 PMC: 10835874. DOI: 10.1186/s10020-024-00789-9.

The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer.

Doan P, Katelaris A, Scheltema M, Hayen A, Amin A, Siriwardana A BMC Urol. 2023; 23(1):68.

PMID: 37118731 PMC: 10148506. DOI: 10.1186/s12894-023-01228-3.

Feasibility and accuracy of prostate cancer risk calculators in prediction of prostate cancer, extraprostatic extension as well as the risk of lymph nodes metastasis.

Kulik K, Brzoska R, Mazurek E, Ostrowska M, Ostrowski A, Kowalski F Cent European J Urol. 2023; 76(1):20-24.

PMID: 37064260 PMC: 10091896. DOI: 10.5173/ceju.2023.168.

References

Blute M, Bergstralh E, Partin A, Walsh P, Kattan M, Scardino P . Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000; 164(5):1591-5. View

Partin A, Kattan M, Subong E, Walsh P, Wojno K, Oesterling J . Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277(18):1445-51. View

Penson D, Grossfeld G, Li Y, Henning J, Lubeck D, Carroll P . How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol. 2002; 167(4):1653-7; discussion 1657-8. View

Han M, Snow P, Epstein J, Chan T, Jones K, Walsh P . A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology. 2000; 56(6):994-9. DOI: 10.1016/s0090-4295(00)00815-3. View

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

Eskicorapci S, Karabulut E, Turkeri L, Baltaci S, Cal C, Toktas G . Validation of 2001 Partin tables in Turkey: a multicenter study. Eur Urol. 2005; 47(2):185-9. DOI: 10.1016/j.eururo.2004.08.002. View

Epstein J . Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol. 2000; 24(4):477-8. DOI: 10.1097/00000478-200004000-00001. View

Wang L, Hricak H, Kattan M, Chen H, Scardino P, Kuroiwa K . Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology. 2005; 238(2):597-603. DOI: 10.1148/radiol.2382041905. View

Epstein J, Pizov G, Walsh P . Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993; 71(11):3582-93. DOI: 10.1002/1097-0142(19930601)71:11<3582::aid-cncr2820711120>3.0.co;2-y. View

10.

Makarov D, Humphreys E, Mangold L, Walsh P, Partin A, Epstein J . Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. J Urol. 2006; 176(2):554-8. DOI: 10.1016/j.juro.2006.03.058. View

11.

Partin A, Yoo J, Carter H, Pearson J, Chan D, Epstein J . The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150(1):110-4. DOI: 10.1016/s0022-5347(17)35410-1. View

12.

Blute M, Nativ O, Zincke H, Farrow G, Therneau T, Lieber M . Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol. 1989; 142(5):1262-5. DOI: 10.1016/s0022-5347(17)39051-1. View

13.

Harrell Jr F, Califf R, Pryor D, Lee K, Rosati R . Evaluating the yield of medical tests. JAMA. 1982; 247(18):2543-6. View

14.

Han M, Partin A, Pound C, Epstein J, Walsh P . Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28(3):555-65. DOI: 10.1016/s0094-0143(05)70163-4. View

15.

Aleman M, Karakiewicz P, Kupelian P, Kattan M, Graefen M, Cagiannos I . Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology. 2003; 62(1):70-4. DOI: 10.1016/s0090-4295(03)00125-0. View

16.

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

17.

Kattan M, Eastham J, Wheeler T, Maru N, Scardino P, Erbersdobler A . Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003; 170(5):1792-7. DOI: 10.1097/01.ju.0000091806.70171.41. View

18.

Cagiannos I, Karakiewicz P, Eastham J, Ohori M, Rabbani F, Gerigk C . A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003; 170(5):1798-803. DOI: 10.1097/01.ju.0000091805.98960.13. View

19.

Ohori M, Kattan M, Koh H, Maru N, Slawin K, Shariat S . Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol. 2004; 171(5):1844-9. DOI: 10.1097/01.ju.0000121693.05077.3d. View

20.

Han M, Partin A, Chan D, Walsh P . An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol. 2003; 171(1):23-6. DOI: 10.1097/01.ju.0000098604.09395.27. View